Stopping Metformin When You Get Pregnant: When and How

You just got a positive test. You are looking at your metformin bottle and asking your phone whether you take tomorrow morning's dose, and you want a clear answer. The clear answer is that you should take it, and then call your RE or OB within a week to make a real decision together. The old reflex of "stop at the positive test" is no longer the universal answer it used to be.

When patients ask how long to take metformin for PCOS to get pregnant, they often mean two questions at once. One is how long before the drug starts helping (about 8 to 12 weeks of pre-treatment at target dose, covered in the pillar post). The other is what happens at the positive test. This post is about the second question. The honest answer is that the field has shifted in the past decade, the guidelines now allow either path, and the right decision depends on why you were on metformin in the first place.

What used to be standard

For most of the 2000s and into the 2010s, the standard reflex in fertility clinics was to stop metformin at the first positive pregnancy test. The reasoning was understandable. Metformin is a drug that crosses the placenta, the human data on first-trimester exposure were limited, and the cautious move was to remove an unnecessary medication during a window when the embryo is most sensitive.

The problem was that "unnecessary" was assumed, not established. For patients whose metformin was prescribed solely as an ovulation-induction adjunct, stopping at positive made sense. For patients whose metformin was treating ongoing insulin resistance, prediabetes, or prior gestational diabetes, stopping at positive removed an active metabolic treatment at the moment metabolic stress was about to increase.

What changed the conversation

Several things have shifted the field over the past fifteen years.

Safety data accumulated. Metformin is FDA pregnancy category B (no animal-study harm, limited human data at the time of original labeling), and the human data have continued to accumulate without a safety signal in the published literature.¹, ², ⁵ Large follow-up studies of children exposed in utero, including the MiG TOFU offspring follow-up at 7 to 9 years, have not shown developmental concerns compared with control children.³

Use in gestational diabetes became routine. Metformin is now widely used in the second half of pregnancy for gestational diabetes management, in many cases as a first-line oral option alongside insulin.⁵ If the drug is safe enough for routine use at 28 weeks, the case for blanket avoidance at 6 weeks weakened.

Trial data emerged on continuation. The PregMet trial in 2010, led by Vanky and colleagues, randomized 257 women with PCOS to metformin or placebo from first trimester to delivery.¹ The primary outcome (composite preeclampsia, preterm birth, gestational diabetes) did not differ significantly between groups. Subsequent PregMet2, published in Lancet Diabetes & Endocrinology in 2019, randomized 487 women.² It showed lower gestational weight gain and a non-significant trend toward fewer late miscarriages in the metformin group, without safety concerns.

The 2023 International Evidence-Based Guideline for PCOS by Teede and colleagues now states that continuation of metformin through pregnancy may be considered in patients with PCOS, on a case-by-case basis, particularly for those with metabolic indications.⁴ The guideline does not say everyone should continue, and it does not say everyone should stop. It opens the door to either path.

The MiTy trial in 2020 looked specifically at metformin added to insulin in women with type 2 diabetes during pregnancy and showed maternal benefits including lower weight gain and lower insulin requirements, with no safety signal on the primary fetal composite outcome.⁶ The broader context here is that metformin in pregnancy now has a substantial body of evidence behind it.

Possible benefits of continuing in early pregnancy

These are the reasons your RE might recommend continuing metformin past the positive test.

• Reduced gestational diabetes risk: PCOS pregnancies carry a higher baseline risk of GDM, and continuation through the first trimester is associated with better metabolic profiles in several cohorts.¹, ²
• Possibly lower miscarriage rate in some PCOS subgroups, particularly with documented insulin resistance. The data here are mixed, with some studies showing benefit and others showing none. Not a guarantee, but a plausible secondary benefit.
• Better glycemic control for patients with prediabetes or type 2 diabetes.
• Lower gestational weight gain, shown in PregMet2.²
• Continuity of metabolic care for patients on metformin long before TTC began.

Possible benefits of stopping

These are the reasons your team might recommend stopping at the positive test.

• Removes any theoretical drug-exposure concern, particularly for patients whose anxiety in the first trimester is already high.
• Eliminates GI side effects during the same window when first-trimester nausea is at its worst. Metformin nausea and pregnancy nausea stacked together are unpleasant.
• Simpler regimen at a time of new prenatal vitamins, new appointments, and new clinical providers.
• No strong evidence that stopping at 8 to 12 weeks harms outcomes in patients whose metformin indication was solely ovulation induction.

What different guidelines say

The international picture is not uniform, and that is partly why your team's recommendation may differ from what you read online.

• ACOG does not currently make a blanket recommendation for or against continuation. The obstetric team makes the call based on indication.
• ESHRE / 2023 International PCOS Guideline: continuation can be considered, particularly for metabolic indications.⁴
• NICE (UK) is more conservative; metformin is not routinely continued in pregnancy outside of gestational diabetes management, but the door is not closed.
• Practice patterns vary by clinic and by country. Many U.S. and European REs continue through the first trimester and then defer to the OB. Many obstetricians stop at the first prenatal visit. Some continue through delivery for selected patients.

This is one of those situations where there is not a single right answer that applies to everyone. There is a right conversation, which is the one with your RE and your OB about your specific profile.

When the answer is usually "continue"

The patients I most often recommend continue metformin into the first trimester are these:

• Type 2 diabetes diagnosed before pregnancy: metformin is part of the broader diabetes plan.
• Prediabetes or impaired glucose tolerance.
• Prior gestational diabetes: higher recurrence risk.
• Active insulin resistance with elevated HOMA-IR and clinical metabolic features.
• Patients who started metformin for metabolic management long before TTC, where the drug was never primarily about fertility.
• Significant obesity with metabolic complications.

In these cases, continuation through the first trimester (often through 12 weeks, then reassessed with the OB) is increasingly standard.

When the answer is usually "stop"

The patients for whom stopping at the positive test still makes sense:

• Metformin started solely for ovulation induction, with no metabolic indication beyond PCOS.
• Normal fasting insulin and HOMA-IR with the only PCOS feature being anovulation.
• Severe morning sickness making the medication unsustainable in the first trimester.
• Lean PCOS where the metabolic case for metformin was weak from the start.
• Patient preference, after a real conversation with the provider.

There is no medical urgency to stop the day of the positive test. The decision is made in the next appointment, not in the bathroom holding the stick.

How to stop or taper

If the decision is to stop, the practical question is whether to taper or simply stop.

• No tapering is required for medication safety reasons. Metformin can be stopped abruptly without rebound effects.
• Some patients prefer a step-down (1500mg to 1000mg to 500mg over a week or two) to reduce any GI rebound, but this is comfort-driven, not necessity.
• Talk to your team within a week of the positive test, before the decision drifts. Most clinics have a metformin-in-early-pregnancy conversation that takes less than ten minutes.
• If you have continued through the first trimester and then decide to stop at the prenatal visit, the same applies: no taper required for safety, taper if it feels easier.

Practical things to track regardless of the decision

Whether you stop or continue, these are worth tracking in early pregnancy with PCOS.

• Early pregnancy beta-hCG, on the schedule your RE recommends.
• Early ultrasound at around 6 to 8 weeks for viability and dating.
• Glucose, if your team wants a baseline check, particularly for patients with prior GDM or insulin resistance.
• Any GI changes, particularly if you continue metformin and morning sickness intensifies.
• First prenatal visit timing and the handoff from RE to OB.

For patients who stopped metformin, glucose screening at 24 to 28 weeks (the standard glucose tolerance test) becomes the next checkpoint. For patients who continued, that test still happens, and the conversation about whether to continue metformin into the second and third trimesters is usually had then.

What about long-term metformin use

A related question that comes up, especially in patients who have been on metformin for years: do you have to take metformin forever for pcos. The honest answer is no, not always. Metformin is a metabolic tool, not a cure. Many patients with PCOS take it during active TTC and stop after delivery and breastfeeding. Others continue long-term for diabetes prevention or for cycle regulation outside of TTC. The decision is individualized, and it is revisited at intervals as the metabolic picture changes.

The flip side question, can metformin help you get pregnant with pcos at all, is one I want to answer directly. The data say yes, modestly, particularly in combination with letrozole and in insulin-resistant subgroups. I cover that in the pillar and the combo post.

What this means for how long to take metformin for PCOS to get pregnant

If you just got a positive test, the immediate plan is straightforward.

1. Take your scheduled dose today. Stopping abruptly without talking to your team first is not necessary.
2. Call your RE within a week. They will tell you whether to continue or stop based on your specific profile, and they will coordinate with your OB if you have one.
3. If you cannot reach your RE quickly, your prescribing physician (the one who wrote for metformin originally) can advise.
4. Bring your indication to the conversation. Was metformin started for ovulation induction only, or were there metabolic reasons. The answer drives most of the decision.
5. Plan the handoff to OB care. Most fertility clinics transition patients to obstetric care around 8 to 10 weeks. The metformin decision is often revisited at that visit.

The newest evidence has made this decision more nuanced, not more confusing. The simple version: if metformin was treating only your ovulation, stopping is reasonable. If metformin was treating your metabolism, continuing into the first trimester is increasingly the standard. Your team makes the call with you, not for you.

What's next

• For the pillar on metformin and PCOS: Metformin for PCOS Fertility: How It Helps and When to Start
• If you were on a combo regimen: Metformin and Letrozole: The PCOS Combination Protocol
• If you want to know what the first 48 hours after a positive test typically involve: BFP: The First 48 Hours
• For the conversation with your RE about a positive test: Telling Your RE Your Test Was Positive

Sources

1. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study (PregMet). Journal of Clinical Endocrinology & Metabolism 2010;95(12):E448-E455. https://doi.org/10.1210/jc.2010-0853
2. Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2019;7(4):256-266. https://doi.org/10.1016/S2213-8587(19)30002-6
3. Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Research & Care 2018;6(1):e000456. https://doi.org/10.1136/bmjdrc-2017-000456
4. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025
5. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics & Gynecology 2018;131(2):e49-e64. https://doi.org/10.1097/AOG.0000000000002501
6. Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2020;8(10):834-844. https://doi.org/10.1016/S2213-8587(20)30310-7